Introduction
The Shiraz Transplant center was established in 1988, the year when the first renal transplant was performed at this center 1 on May 4, 1993 from a deceased donor. 2 Since then, this institute has risen to become a pioneer of most solid-organ transplants in Iran in 2 respects: the number of transplants, and the variety of transplant procedures (eg, deceaseddonor liver transplant, living-donor liver transplant, [3] [4] [5] split liver transplant, 6 pancreas transplant, 7 multivisceral transplant, small bowel transplant, and different kinds of autotransplants such as small bowel, liver, and kidney). Here, we focus on 2011 transplant activities at the Shiraz transplant center.
Materials and Methods
Data for all patients who received transplants at this center in 2011 were collected and reviewed retrospectively. During this time, 345 liver, 297 kidney, 29 pancreas, and 11 intestinal and multivisceral transplants were performed.
Of 345 liver transplants, 291 patients received a deceased-donor graft, which included 18 split liver transplants, while 54 patients received living-donor liver transplants. Among 54 cases of living-donor liver transplant, the majority of recipients were pediatric patients and 9 were adults ( Abbreviations: DDLT, deceased-donor liver transplant; LDLT, living-donor liver transplant
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Of 297 kidney transplants, 256 cases were from deceased donors, while 41 cases were from livingrelated donors. Among 29 cases of pancreas transplant, 11 patients received pancreatic transplant alone, while 18 patients received simultaneous pancreas and kidney transplants.
During this time, we performed 11 intestinal and multivisceral transplants. Three patients who had short bowel syndrome received isolated intestinal transplants, while 8 patients received multivisceral transplants. Out of those 8 patients, 6 underwent modified multivisceral transplants (without liver). Patient demographics are listed in Table 2 .
Ex vivo surgery and autotransplant is a novel technique used to approach patients with tumors considered unresectable by conventional techniques. Using valuable experience in liver and small intestine transplant, we applied this technique in several patients with hepatic tumors and patients with tumors involving the mesenteric vascular pedicle.
Results
The results of all liver transplants done in 2011 at our hospital were analyzed, which showed that after median follow-up of 12 months, the overall mortality rate was 9% (31 patients). One-year graft and patient survival was estimated at 90.1% and 91%. Acute graft failure secondary to primary nonfunction or vascular thrombosis occurred in 6 patients in whom we performed a retransplant. Out of these six, 3 patients (50%) survived. The most-common indications for a liver transplant were hepatitis B virus cirrhosis (17%), cryptogenic cirrhosis (16.7%), and autoimmune hepatitis (14.2%).
Major complications occurred in 38% of the patients: acute rejection (26%), biliary complications (9.5%), convulsion (7%), sepsis (2.9%), hepatic artery thrombosis (3.2%), and portal vein thrombosis (2%). The outcome of kidney transplants was also excellent; only 3 patients died (1%), and 8 grafts (2.7%) were lost mainly because of vascular events.
In pancreas transplants, we had just 1 graft loss owing to arterial thrombosis in a patient with a pancreas transplant alone in whom a pancreatectomy was done. As of this writing, the other recipients are in good condition with good graft function.
We have had 11 intestinal and multivisceral transplants with acceptable outcomes. Among these, we had 3 isolated intestinal transplants, all are alive with functioning grafts. As of this writing, of 8 multivisceral transplants (with and without liver), 4 patients are surviving with good graft function. Although the initial results of ex vivo surgery and autotransplant are promising, long-term follow-up is required to support our research.
Discussion
The annual rate of liver transplants has increased from 14 in 2002 to 345 in 2011 (Figure 1) , while the survival rate of liver transplants has improved to more than 90%, which is comparable to that of major centers throughout the world.
This increase in the rate of liver transplants is due mainly to our strategy to expand the donor pool. We have tried to increase the annual rate of deceasedorgan donation in Iran, and this rate has been increased from 0.3 per million of population in 2000 to more than 5 per million of population in 2011. Also, we have used organs from expanded criteria donors for high-risk recipients. Performing more living-donor liver transplants, split liver transplants, and using more organs from a single deceased donor are other ways that we have used for this purpose.
To promote liver transplant in Iran and other Middle East Society for Organ Transplantation (MESOT) countries, we began a fellowship program in 2005 for surgeons in the field of organ transplantation. We are not only giving fellowships to Iranians, but also giving training to fellows of other MESOT countries. Another step is the construction of Avi-Cenna University Hospital in Shiraz, which hopefully will begin in 2013. In conclusion, our model for organ transplant has been well developed in recent years, and the Shiraz Transplant Center is one of the largest transplant centers in the world ready to collaborate with other centers.
